文献速递垂体与肾上腺疾病

伐莫洛龙与泼尼松在杜氏肌营养不良症中的肾上腺抑制:2b期临床试验结果

Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究为随机双盲安慰剂和泼尼松对照24周试验及其24周交叉扩展的事后分析,纳入118例杜氏肌营养不良症患儿。第24周时,泼尼松0.75 mg/kg/天组肾上腺抑制发生率为100%(25/25,历史阈值)和92.0%(23/25,修订阈值),伐莫洛龙6 mg/kg/天组为95.2%(20/21)和90.5%(19/21),伐莫洛龙2 mg/kg/天组为84.2%(16/19)和47.5%(9/19),安慰剂组为20.0%(4/20)和0%(0/20)。作者推荐对接受伐莫洛龙的患者在应激时使用氢化可的松。

要点

  • 泼尼松0.75 mg/kg/天组肾上腺抑制发生率为100%(25/25,历史阈值)和92.0%(23/25,修订阈值)。
  • 伐莫洛龙6 mg/kg/天组肾上腺抑制发生率为95.2%(20/21)和90.5%(19/21),2 mg/kg/天组为84.2%(16/19)和47.5%(9/19)。
  • 作者推荐对接受伐莫洛龙的患者在应激时使用氢化可的松。

核心结论

  • 伐莫洛龙和泼尼松治疗后肾上腺抑制常见,伐莫洛龙相关肾上腺抑制似乎呈剂量依赖性。
  • 使用单克隆抗体免疫测定时,较低的刺激皮质醇阈值可能更合适。
  • 作者推荐对接受伐莫洛龙的患者在应激时使用氢化可的松。

研究设计与样本

  • 随机、双盲、安慰剂和泼尼松对照的24周试验,含24周交叉扩展,事后分析皮质醇水平。
  • 纳入118例杜氏肌营养不良症患儿,入组平均年龄5.41 ± 0.86岁。
  • 采用Elecsys II免疫测定法检测晨起和ACTH刺激后皮质醇水平。

主要发现

  • 第24周时,泼尼松0.75 mg/kg/天组肾上腺抑制发生率(历史阈值)为100%(25/25),修订阈值为92.0%(23/25)。
  • 第24周时,伐莫洛龙6 mg/kg/天组肾上腺抑制发生率(历史阈值)为95.2%(20/21),修订阈值为90.5%(19/21)。
  • 第24周时,伐莫洛龙2 mg/kg/天组肾上腺抑制发生率(历史阈值)为84.2%(16/19),修订阈值为47.5%(9/19)。
  • 第24周时,安慰剂组肾上腺抑制发生率(历史阈值)为20.0%(4/20),修订阈值为0%(0/20)。
  • 在接受类固醇治疗的男孩中,晨起皮质醇与ACTH刺激后峰值皮质醇强相关(第48周Spearman相关系数=0.83)。

关键数值与推荐

  • 肾上腺抑制定义为ACTH刺激后皮质醇<500 nmol/L(历史阈值)或<400 nmol/L(修订阈值)。

临床怎么用

  • 作者推荐对接受伐莫洛龙的患者在应激时使用氢化可的松进行应激剂量给药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Vamorolone, a novel "dissociative" steroid, demonstrated similar efficacy in muscle function relative to prednisone 0.75 mg/kg/day but improved linear growth and bone turnover markers in a randomized trial of pediatric Duchenne muscular dystrophy (DMD). OBJECTIVES: To determine the frequency of adrenal suppression (AS) induced by vamorolone and prednisone in pediatric DMD and to assess cortisol thresholds using a monoclonal antibody immunoassay. METHODS: Post hoc analysis of cortisol levels was performed on data from a randomized, double-blind, placebo- and prednisone-controlled 24-week trial of vamorolone with a 24-week crossover extension. Morning and ACTH-stimulated cortisol levels were measured using the Elecsys II immunoassay, with AS defined as a stimulated cortisol of <500 nmol/L ("historical threshold") and <400 nmol/L ("revised threshold"). RESULTS: Mean age at enrolment was 5.41 ± 0.86 years (n = 118). At week 24, the proportion of participants with AS using the historical and revised cortisol thresholds, respectively, were as follows: prednisone 0.75 mg/kg/day = 100% (25/25) and 92.0% (23/25); vamorolone 6 mg/kg/day = 95.2% (20/21) and 90.5% (19/21); vamorolone 2 mg/kg/day = 84.2% (16/19) and 47.5% (9/19); and placebo = 20.0% (4/20) and 0% (0/20). Morning and peak ACTH-stimulated cortisol were strongly correlated in steroid-treated boys (Spearman correlation week 48 = 0.83). CONCLUSION: AS after vamorolone and prednisone was frequent and vamorolone-associated AS appeared dose-dependent. A lower stimulated cortisol threshold may be appropriate when using a monoclonal assay. We recommend hydrocortisone for glucocorticoid stress dosing in patients receiving vamorolone.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ahmet A, Tobin R, Dang UJ, et al. Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial. J Clin Endocrinol Metab. 2025. PMID: 39097643. doi:10.1210/clinem/dgae521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。